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Abstract: 
A recent meeting of Health Ministers from over 40 countries worldwide 
deemed that time and money should be spent on outcome and experience 
measures that would allow us to determine whether our health systems 
deliver outcomes that truly matter to patients. This meeting along with recent 
national programmes to promote the use of outcome measures in evaluating 
medical and surgical interventions highlight the important role that patient 
reported outcome measures (PROMs) and patient reported experience 
measures (PREMs) have in healthcare. Oral Medicine as a specialty has 
promoted the use of PROMs to some extent in the recent past with the use of 
generic and oral health specific measures in the literature and the delivery of 
plenary lectures at international scientific meetings. We could find no 
publications regarding the use of PREMs in Oral Medicine. This article 
highlights the commonly used PROM tools in the oral mucosal disease and 
salivary gland literature and makes recommendations for the evaluation of the 
development properties of currently used instruments and the establishment 
of core outcome sets in the commonly managed conditions in an Oral 
Medicine setting. It is also hoped that by looking at the types of PREM tools 
available we can be to determine a suitable instrument for the evaluation of 
patient experience in Oral Medicine practice.  
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Introduction 
In early 2017, following a meeting in Paris, Health Ministers from the 
Organisation for Economic Co-operation and Development (OECD) in 
addition to representatives from Argentina, Colombia, Costa Rica, 
Kazakhstan, Lithuania, Peru and South Africa declared that we need to 
devote time and money to tools that will allow us to determined whether our 
health systems deliver outcomes that truly matter to patients.  This statement 
represents a shift from the historical dependence in medicine and dentistry on 
mortality rates and clinician reported outcomes, which provide a one-
dimensional perspective on the care provided. The consensus from this 
meeting to determine the ‘Next Generation of Health Reforms’ was that we 
need to invest in ‘cross-country comparative measures of patients’ own 
experience of medical care and health care outcomes’ therefore emphasising 
the need for robust patient reported experience measures (PREMs) and 
patient reported outcomes measures (PROMs) in clinical practice1. Coulter et 
al defined a PREM as a measure of a patient’s perception of their personal 
experience of the healthcare they have received, focusing on the aspects of 
the care that matter specifically to the patients2. While a PROM is a tool that 
allows patients to self-assess their own health ensuring no external influences 
the report of this assessment 3, 4. It can provide ‘an insight into the way 
patients perceive their health and the impact that treatments or adjustments to 
lifestyle have on their quality of life’ 3, 5.  
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Recording and acting upon aspects of healthcare that matter most to patients 
is laudable, and it would appear soon to be compulsory, but 2 key practical 
questions are remain -  
1. what is the patient perception of the use of PROMs and PREMs 
2. is it practical in a clinical setting 
A number of acceptability and feasibility studies have been carried out to 
explore the logistics of the incorporation of these tools into clinical practice 6-8. 
In a series of qualitative interviews with patients regarding the use of PROMs 
in colorectal cancer clinics patients highlighted that PROM use can 
sometimes bring to the fore issues they may have overlooked as being of 
significance with regard to the impact of the disease on their lives. The 
patients were also undeterred by the time taken to complete PROMs and it 
was agreed by patients and clinicians interviewed that PROMs used in clinical 
practice could facilitate the provision of critical psychological and emotional 
support needed by patients with chronic illness 7.  
  
As a specialty, Oral Medicine has certainly begun to promote the use of 
PREMs and PROMs in clinical practice and research in the last number of 
years via our national and international Oral Medicine organizations and their 
associated periodic scientific meetings. A plenary session was dedicated to 
PREMs, PROMs and clinician reported outcome measures (CROMs) specific 
to Oral Medicine at the British Society of Oral Medicine (BSOM) Annual 
Scientific Meeting in Liverpool in 2012. This session included examples of the 
positive effect of PREMs used in clinical practice in Liverpool along with 
information regarding PROM usage in the oral medicine literature. Soon 
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afterward an Oral Medicine Practice Group was established for the 2014 6th 
World Workshop in Oral Medicine (WWOM VI), a group tasked with aims 
including exploring PROM used in oral mucosal disease, providing direction 
for future PROMs in Oral Medicine clinical practice and research and 
conducting a multi-centre cross-sectional study using oral medicine specific 
PROMs and CROMs in patients with oral lichen planus 9, 10. Focusing on 
immune-mediated disease, the 2016 European Association of Oral Medicine 
(EAOM) 13th Biennial Congress highlighted the importance of outcome 
measures in the management of patients with vesiculobullous diseases, again 
in a plenary session 10. In addition to the promotion of PROM and PREM use 
at Oral Medicine scientific meetings the National Health Service (NHS) 
Commissioning Guide for Oral Surgery and Oral Medicine, published in 2015, 
recommended the use of outcome and experience measures in regular 
clinical practice 11. So although we have not extensively devoted time and 
money to PROM and PREM instruments in Oral Medicine, as recommended 
by the Health Ministries, we have certainly acknowledge the importance of 
determining healthcare outcomes that truly matter to our patients. The aims of 
this article are to summarise the literature regarding PREM use and PROM 
use in Oral Medicine, focusing on mucosal disease and salivary gland 
disease.  
 
 
PROMs in Oral Medicine 
Black reported that the integration of PROMs into clinical practice could 
transform healthcare, emphasizing potential improvements in clinical decision-
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making and service enhancements with the routine use of PROMs 12. For 
PROMs to be of transformative in the delivery patient care they must have 
included the patient in determining its content and undergone a robust 
development process. Patient input in the generation of PROM items is 
surprisingly uncommon with only 10% of tools recently reviewed incorporating 
patient opinion on which outcomes should be measured 13. PROM 
development includes demonstrating evidence of psychometric properties 
including validity (ability of a PROM to measure the predetermined underlying 
concept), reliability (ability of a PROM to consistently generate reproducible 
scores) and responsiveness (ability of a PROM to detect a change in the 
concept being measured over time) in the appropriate patient population 14.  
Table 1 summarises the PROMs commonly used in oral mucosal disease 
while table 2 provides an overview of the PROMs commonly used in salivary 
gland disease.  Both tables highlight the evidence for validity and reliability in 
Oral Medicine specific patient populations.  
 
Assessment of Symptoms 
Patient reported assessment of therapeutic interventions in Oral Medicine is 
often limited to symptom severity scales 9. For example pain is one of the 
most common complaints of patients with oral mucosal diseases seeking 
clinical intervention. Patients may describe their mucosal pain using various 
terms including as “burning sensation”, “soreness”, “itching” or “stinging 15. 
There is currently no oral symptom-PROM developed specifically for any oral 
mucosal conditions. The majority of clinical trials of oral mucosal diseases 
used a visual analog scale (VAS) or numerical rating scale (NRS) for the 
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assessment of pain intensity 9. VAS requires patients to mark a point on a 10-
cm horizontal line, labeled as ‘no pain’ on one end and ‘worst pain possible’ 
on the other end, that best reflects the degree of pain experienced, with VAS 
scores ranging from 0 to 10cm in a continuous scale. NRS, on the other hand, 
is a segmented numeric version of VAS, with patients are asked to select one 
of whole numbers from 0 to 10 16. The validity of VAS and NRS have been 
investigated in patients with oral lichen planus (OLP) in one study and the 
results showed better construct validity of NRS over VAS 17.  
 
Patients with salivary gland diseases may present with salivary gland 
hypofunction and xerostomia. In fact xerostomia, the patient reported 
sensation of dry mouth, is reported in up to 20% of adults 18. As highlighted by 
Thomson et al, a single question, asking a patient to rate the severity of their 
dry mouth, would fail to divulge the collection of symptoms that present in 
patients with xerostomia 19. The Xerostomia Inventory (XI) is a tool developed 
in the late 1990s and further refined to a shortened version (SXI-D) to 
determine the symptoms related to dry mouth providing a more 
comprehensive overview of symptomatology than a single VAS rating of oral 
dryness 20, 21. In an article regarding the diagnosis and management of 
xerostomia by Villa et al the authors found 5 instruments developed to assess 
dry mouth including the aforementioned XI 22. These tools record prevalence 
23, frequency 24 and severity 25 of xerostomia. There has been no 
comprehensive review of the psychometric properties of these instruments 
therefore no comment can be made on whether these instruments have been 
robustly developed.  In patients with Sjögren’s Syndrome (SS) symptom 
 8 
assessment tools include the Liverpool Sicca Index and the Sicca Symptoms 
Inventory. These tools are not limited to oral dryness and include 
assessments of ocular and vaginal dryness also 26. Most recently the 
European League Against Rheumatism (EULAR) SS study group recently 
developed a patient reported index (ESSPRI) to measure symptoms of SS 27. 
The symptoms assessed in this tool include dryness, pain and fatigue.   
 
Assessment of Psychosocial Aspects of Disease and Quality of Life 
Oral mucosal diseases have been shown to have negative impacts on 
psychosocial status and quality of life (QoL) of patients 28. According to a 
qualitative study on patients with chronic oral mucosal diseases, a majority of 
patients reported difficulties with daily activities due to oral symptoms as well 
as limitation on certain foods can results in psychological distress and issues 
on social participations 29. Assessment of psychosocial status and QoL using 
PROMs in patients with oral mucosal diseases should therefore not be 
neglected.  
 
A number of generic psychosocial-PROMs have been used in clinical studies 
of oral mucosal diseases, and these instruments measure different 
psychosocial constructs such as anxiety, depression, stress, distress, coping 
with illness, psychological well-being, vulnerability, mood, loneliness, anger, 
and social support 9, 30-32. Of these construct, anxiety and depression are 
generally the two most commonly assessed psychosocial construct in the 
literature. Three frequently used PROMs measuring anxiety and/or 
depression include Hospital Anxiety and Depression Scale (HADS), State-
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Trait Anxiety Inventory (STAI) and Beck Depression Inventory (BDI) 9. Both 
BDI and HADS were provided as examples of clinical outcomes measures of 
pain measurement used in research in the aforementioned NHS 
Commissioning Guide 11, however, none of these PROMs have been 
psychometrically examined in patients with oral mucosal diseases.  
 
QoL can be evaluated through the use of generic-QoL, oral health related 
QoL (OH-QoL) PROMs and disease-specific-QoL PROMs. Two commonly 
used generic-QoL PROMs in oral mucosal diseases are the 36-item an 12-
item Short Form Health Survey (SF-36, SF-12), both of which measure 
general aspects of QoL including vitality, physical functioning, bodily pain, 
general health perceptions, physical functioning, emotional functioning, social 
functioning and mental health 9, 33. OH-QoL PROMs comprise items that 
predominantly focus on patients’ perception of QoL aspects with respect to 
their oral health. A number of instruments have been used in clinical studies 
of oral mucosal diseases including the 14-item and 49-item Oral Health 
Impact Profile (OHIP-14, OHIP-49), the Oral Health-related Quality Of Life-UK 
(OHQOL-UK) and the Oral Impacts on Daily Performance (OIDP) 9. Both 
generic and oral health specific QOL tools were highlighted as well validated 
and commonly used in the NHS Commissioning Guide, specifically referring 
to SF-12, SF-20 and SF-36 along with OHIP-14 and OHIP-49 11. When 
reviewing the psychometric properties of these QOL instruments in Oral 
Medicine we can found that only OHIP-14 and OHQOL-UK have been 
examined for their psychometric properties in OLP and RAS populations 34. At 
present only one discipline-specific PROMs was identified in the literature. 
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The Chronic Oral Mucosal Disease Questionnaire (COMDQ) is a recently 
developed oral medicine-specific PROM for the assessment of QoL in 
patients with chronic oral mucosal disease. The COMDQ was produced 
following extensive review of the current literature, input from oral medicine 
experts and input from patients with chronic oral mucosal diseases including 
OLP, recurrent aphthous stomatitis (RAS), pemphigus vulgaris (PV), mucous 
membrane pemphigoid (MMP) and orofacial granulomatosis (OFG) via 
qualitative interviews 35. The COMDQ comprises 26 items addressing 4 key 
domains including pain and functional limitation, medications and side effects, 
social and emotional and patient support. The COMDQ has been shown to 
have highest number of validation studies and psychometric properties tested 
(content validity, convergent validity, discriminant validity, internal 
consistency, test-retest reliability, responsiveness) in oral mucosal diseases 
and can be recommended for use in both clinical and research setting to 
assess QoL in patients with chronic oral mucosal diseases 35-39. 
 
Numerous studies have been published exploring psychological status and 
QoL in patients with salivary gland disease. These studies can broadly be 
categorised into 3 types – general xerostomia, SS and xerostomia secondary 
to radiotherapy. Similar tools have been employed these studies including 
HADS 40, SF-36 41, 42 OIDP 43 and OHIP-14 44, 45. A xerostomia specific QoL 
tool, XeQoLS, was developed the 1990s. It is a 15-item questionnaire 
consisting of 4 domains namely physical function, psychological function, 
social function and pain issues measured with a 5-point likert scale46. The 
psychometric properties have been tested and described in a patient group 
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with radiotherapy-induced xerostomia (RIX) 47-49. In an extensive review of the 
methods of measuring RIX by Eisbruch et al 50 also highlight the incorporation 
of questions relating to xerostomia in a number of head and neck cancer 
specific QoL instruments. The most commonly used tools51 were EORTC 
module for head and neck cancer 52 and the University of Washington Quality 
of Life questionnaire 53. The psychometric properties of these head and neck 
specific tools have been extensively reviewed using the Scientific Advisory 
Committee of the Medical Outcomes Trust (SAC-MOT) tool 51.  
 
PREMs in Oral Medicine  
As there is a dearth of literature regarding the use of PREMs in Oral Medicine 
we need to begin by looking at PREMs in general, their application and what 
is considered important to record when implementing these tools in clinical 
practice. Manary et al highlight the prominent role of PREMs in research and 
the determination of healthcare policy, stating that when these tools are 
designed and administered appropriately they can prove to be robust 
indicators of the quality of healthcare being provided 54.  Although PREMs are 
more commonplace, the lack of consensus regarding a universal definition of 
the components or underlying concept of the ‘patient experience’ leads to 
numerous diverse PREM tools being available for use 55. In addition to the 
diversity of the tools available there remain 3 fundamental points of concern 
regarding the merits of PREMs 54 –  
1. feedback from patients is thought by some to lack credibility as it must be 
remembered that patients are not medically trained 
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2. PREMs may be confounded by elements not associated with the quality of 
the healthcare provided but rather an evaluation by the patient of their current 
health status independent of the care received 
3. patients may evaluate their healthcare experience based on the fulfilment 
of predetermined expectations of treatment interventions. 
In spite of these concerns and controversies the incorporation of PREMs into 
clinical practice is being promoted at national level. The National Health 
Service (NHS) Friends and Family Test has been incorporated in the clinical 
practice in the UK in recent years. It consists of a single question, ‘How likely 
are you to recommend our ward/department to friends and family if they 
needed similar care or treatment?’, with a 6-point response scale (Extremely 
likely, Likely, Neither likely nor unlikely, Unlikely, Extremely unlikely, Don’t 
know) 56. When appropriately developed PREMs allow the inclusion of the 
patient voice in a simple, quantifiable and reproducible way 2. Coulter et al 
highlight the importance of not only recording a rating of the patient 
experience of care but also determining the details of the patients’ experience 
to allow us to shape any resultant quality improvement 2. In recording these 
evaluations of patient experience we must also commit to act on the findings 
57.  
 
The PREM tools currently recording these patient interactions can be broadly 
categorised into inpatient experience measures, primary care experience 
measures and outpatient experience measures 58. Extensive work has been 
carried out by the Picker Institute regarding PREMs including outlining the key 
domains required for each of the 3 aforementioned categories 59. Looking at 
 13 
outpatient experience, as it is most align to Oral Medicine practice in the UK, 
the key domains for priority attention included ‘dealing with issues for which 
patients presented themselves, doctors, cleanliness, other professionals, 
information about discharge, information about treatment’ 60. PREMs are not 
limited to the clinical setting in which they are administered with a recent 
publication outlining the development of a tool evaluating the experience of 
paediatric patients with diabetes 61. The NHS Commissioning Guide outlines 7 
questions suitable for use with Oral Surgery and Oral Medicine patients, 
which include provision of information regarding treatment, the provision of 
information regarding the merits of an intervention, the provision of 
information regarding adverse effects of medications prescribed and the 
provision of post operative instruction avoiding jargon along with appropriate 
management of pain and anxiety intraoperatively 11. 
 
Conclusion 
Although Oral Medicine as a speciality has somewhat embraced the use of 
PROMs, as evidenced in the literature discussed in this article, we have 
achieved little with regard to ensuring the tools we use are robust and fit for 
purpose. Evaluation of the development process and psychometric properties 
of instruments commonly used in Oral Medicine could be conducted using 
checklists such as SAC-MOT 62 or the COnsensus-based Standards for the 
selection of health Measurement INstruments (COSMIN) 63. This would allow 
us to be confident that the scores generated from PROMs are valid, reliable 
and responsive to change. Further work is also needed to achieve a 
consensus on the PROMs that should be used consistently in research or in 
 14 
clinical practice. This process of determining a consensus on outcome 
measures used in research and clinical practice could facilitate meta-analysis 
of data from clinical trials leading to more robust evidence for the 
management of oral disease in an oral medicine setting 64. Taylor et al has 
undertaken this consensus process in determining a Core Outcome Set 
(COS) in recurrent aphthous stomatitis (RAS) which could help direct the 
speciality in applying this methodology to other common conditions in Oral 
Medicine 10.  Considerable work is needed when evaluating the patient 
experience in Oral Medicine with recommendation for the use of the Picker 
Institute outpatient experience tool as a starting point for future PREM 
research.  
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Table 1 Summary of commonly used PROMs in oral mucosal diseases 
PROM 
Items  
(N) 
Rating 
scale 
Dimensions  
evaluated 
psychometric/validation evidence in 
population of oral medicine setting  
(country, No of patients) 
References 
Oral symptom-specific 
NRS 1 0-10 pain OLP (US, 33) Chainani-Wu et al, 2008 17 
VAS 1 0-100 mm 
or  
0-10 cm 
pain OLP (US, 33) Chainani-Wu et al, 2008 17 
Psychosocial-specific 
BDI 21 4-point 
scale 
depression No evidence  - 
HADS 14 4-point 
scale 
anxiety,  
depression 
No evidence  - 
STAI 40 4-point 
scale 
anxiety No evidence  - 
QoL-specific         
COMDQ 26 5-point 
scale 
QoL specific 
 to COMD 
OLP (China, 72; Ireland, 109; UK, 100),  
RAS (China, 84; Ireland, 12; UK, 42), 
PV or MMP (China, 36; Ireland, 6; UK, 
58) 
OFG (China; 8; Ireland, 7) 
Ni Riordain and McCreary, 2011 
36 
Ni Riordain et al, 2011 35 
Ni Riordain and McCreary, 2012 
37 
Li and He, 2013 38 
Ni Riordain et al, 2016 39 
OHIP-14 14 5-point 
scale 
OH-QoL OLP (UK, 48), RAS (Turkey, 28) Hegarty et al, 2002 65 
McGrath et al, 2003 34 
Mumcu et al, 2006 66 
Mumcu et al, 2007 67 
OHIP-49 49 5-point 
scale 
OH-QoL No evidence  - 
OHQOL-
UK 
16 5-point 
scale 
OH-QoL OLP (UK, 48), RAS (Turkey, 24) Hegarty et al, 2002 65 
McGrath et al, 2003 34 
Mumcu et al, 2006 66 
OIDP 8 6-point 
scale 
OH-QoL No evidence  - 
SF-36 36 2- to 6-point 
scale 
general QoL RAS (Turkey, 24) Mumcu et al, 2006 66 
SF-12 12 2- to 6-point 
scale 
general QoL No evidence  -  
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Table 2 Summary of commonly used PROMs in salivary gland diseases 
PROM 
Items  
(N) 
Rating scale 
Dimensions  
evaluated 
psychometric/validation evidence in 
population of oral medicine setting  
(country, No of patients) 
References 
Symptom-specific 
ESSPRI 3 0-10 
numerical 
 scale 
dryness, fatigue, 
limb pain 
PSS (Argentina, Brasil, France, 
Germany, Greece, Italy, Japan, The 
Netherlands, Norway, Slovenia, Spain, 
Sweden, UK and USA, 395) 
Seror et al, 2015 68 
Liverpool  
 Sicca      
 Index 
28 4-point scale sicca symptoms 
(xerostomia, 
ocular dryness, 
vaginal dryness, 
sensory change) 
PSS (UK, 40) 
Xerostomia (UK, 40) 
Field et al, 2003 69 
Sicca 
 Symptoms 
 Inventory 
42 5- to 7-point  
 scale 
sicca symptoms 
(xerostomia, 
ocular dryness, 
vaginal dryness 
skin dryness) 
PSS (UK, 130) Bowman et al, 2003 70 
SXI-D 5 3-point scale xerostomia Older adults (Australia, 882; Japan, 401; 
The Netherland, 50; New Zealand, 253) 
Xerostomia (China, 212) 
Thomson et al, 2011 21 
van der Putten et al, 2011 24 
He et al, 2013 71 
VAS-XQ 8 0-100 mm or  
0-10 cm 
scale 
xerostomia Older adults (US, 18) Pai et al, 2001 72 
XI 11 5-point scale xerostomia Older adults (Australia, 636) 
Xerostomia (Spain, 41) 
PSS (Portugal, 30; Korea, 194) 
RIX (New Zealand, 57) 
Thomson et al, 1999 19 
Thomson and Williams, 2000 20 
Thomson, 2007 73 
da Mata et al, 2012 74 
Lee et al, 2016 75 
Serrano et al, 2016 76 
XQ by Fox  
 et al 
4 yes/no xerostomia Xerostomia (US, 100) Fox et al, 1987 23 
Psychosocial-specific 
HADS 14 4-point scale anxiety,  
depression 
No evidence  - 
QoL-specific         
EORTC     
 QLQ-C30 
30 4-point scale, 
 yes/no 
QoL specific to  
 H&N cancer 
H&N cancer (Norway, 126) Bjordal and Kaasa, 1992 52 
Ojo et al, 2012 51 
OHIP-14 14 5-point scale OH-QoL No evidence  - 
OIDP 8 6-point scale OH-QoL No evidence  - 
SF-36 36 2- to 6-point 
 scale 
general QoL No evidence  - 
UWQOL 16 3- to 6-point  
 scale 
QoL specific to  
 H&N cancer 
H&N cancer (UK, 145) Rogers et al, 2002 53 
Ojo e al, 2012 51 
XeQoLS 15 5-point scale QoL specific to  
 xerostomia 
RIX (US, 20) Henson et al, 2001 46 
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